Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5679 Target Snapshot

Serine/threonine-protein kinase Nek3 · SINGLE PROTEIN · Homo sapiens

695Compounds
165Assays
5Approved Drugs
338.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P51956. Use UniProt P51956 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P51956 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase Nek3 as ChEMBL target CHEMBL5679, mapped to UniProt P51956. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase Nek3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5679
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P51956
Serine/threonine-protein kinase Nek3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase Nek3 is the right protein anchor across sources, using UniProt P51956 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase Nek3
UniProt AccessionP51956
Component TypeProtein
Sequence Length506 aa

Serine/threonine-protein kinase Nek3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase Nek3, mapped to UniProt P51956. Sequence length is 506 aa.

Mapped IDP51956
Review nameSerine/threonine-protein kinase Nek3
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

5
Approved
1
Phase III
6
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC5015.0
KI2.0
KD321.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL475251 6.77 Kd 170.0 Clinical
CHEMBL5575113 6.61 IC50 245.0 Preclinical
CHEMBL1078178 6.54 Kd 286.0 Approved
CHEMBL3545328 6.45 Kd 353.0 Preclinical
CHEMBL1287853 6.19 Kd 640.0 Approved
CHEMBL513909 6.14 Kd 720.0 Clinical
CHEMBL1976040 6.08 Kd 837.0 Clinical
CHEMBL482967 6.08 Kd 830.0 Preclinical
CHEMBL4088216 6.0 IC50 1000.0 Preclinical
CHEMBL4097778 6.0 IC50 1000.0 Preclinical
Distribution

pChEMBL Value Distribution

3
5.0
7
5.5
11
6.0
4
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

MOMELOTINIB
CHEMBL1078178
Approved 2023
FEDRATINIB
CHEMBL1287853
Approved 2019
Assay Landscape

Assay Landscape

165
Total Assays
26
Tested Compounds
1
Assay Types
Binding — 165 assays, 26 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 120 15 5.7
assay format 17 0
subcellular format 15 11 5.7
cell-based format 13 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine